Google
Trusted Resources: News & Events
Latest announcements and gatherings
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell Disease
MaxCyte, a US-based global company dedicated to driving the acceleration of discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today it will present positive preclinical study results at the American Society of Gene and Cell Therapy Annual Meeting (ASGCT). The new in vitro data demonstrate the potential of MaxCyte’s cGMP-compliant proprietary delivery platform to enable CRISPR gene editing in the treatment of sickle cell disease (SCD). The ASGCT meeting will take place in Washington, DC from May 10-13, 2017.
+myBinderRelated Content
-
Experimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
-
Effects of Hydroxyurea Treatment for Patients With Hemoglobin SC DiseaseAlthough hemoglobin SC (HbSC) disease is...
-
Update of hematopoietic cell transplantation for sickle cell diseasePURPOSE OF REVIEW: Hematopoietic cell t...
-
Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)AmerisourceBergen, a global healthcare s...
-
My Red Cell Exchangehttps://www.youtube.com/watch?v=HTcLwgLE...
-
Hardships, and New Hope, for Sickle Cell PatientsSickle cell disease affects about 100,00...
-
Is Your Child the Right Candidate for Hydroxyureahttps://www.youtube.com/watch?v=vMvC5rVH...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.